Topics

Glioblastoma | Treatment | Clinical trials | Relatlimab (Anti-lymphocyte activation gene 3)

Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Relatlimab

Lim M, Ye X, Piotrowski AF, Desai A, Ahluwalia MS, Walbert T, Lesser G, Ellingson BM, Peereboom DM, Fisher JD, Desideri S, Jackson C, Pant A, Jain A, Verma R, Oberlton B, Piyadasa H, Bettegowda C, Engle L, Taube J, Bendall SC, Choi J, Drappatz J, Lieberman FS, Kleinberg LR, Pardoll DM, Nabors LB, Wen PY, Grossman SA.
Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.
Nat Med. 2026 Jul 10;32(7):2449-2460. doi: 10.1038/s41591-026-04475-7. PMID: 42432293. Trial registration ID: NCT02658981. ˍ